BeOne Medicines Ltd
123 hedge funds and large institutions have $6.12B invested in BeOne Medicines Ltd in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 11 closing their positions.
455% more call options, than puts
Call options by funds: $58.2M | Put options by funds: $10.5M
282% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 11
127% more capital invested
Capital invested by funds: $2.69B → $6.12B (+$3.43B)
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
32% more funds holding
Funds holding: 93 → 123 (+30)
8% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 37
0.57% more ownership
Funds ownership: 4.66% → 5.23% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$268M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$213M |
| 3 |
Temasek Holdings
Singapore
|
+$134M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$85.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$93M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.4M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$24.4M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$19M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$15.6M |
ONC Hedge Fund Activity: Q1 2018 in Review
123 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q1 2018, worth a combined $6.12B — up 127% from $2.69B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ONC positions and 11 closed out — a net gain of 31 holders — while 40 added to existing stakes and 37 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $268M. The largest seller was OrbiMed, cutting an estimated $93M.
- 123 institutional investors held BeOne Medicines Ltd (ONC) as of Q1 2018, up from 93 in Q4 2017.
- Funds reported $6.12B of BeOne Medicines Ltd stock for Q1 2018, up 127% quarter-over-quarter.
- 42 funds opened new BeOne Medicines Ltd positions in Q1 2018 and 11 closed out, a net change of +31 holders.
- The largest BeOne Medicines Ltd buyer in Q1 2018 was Baker Bros. Advisors, an estimated $268M added.
- The largest BeOne Medicines Ltd seller in Q1 2018 was OrbiMed, an estimated $93M sold.
Based on aggregated 13F filings for Q1 2018.